CPT code 87531 represents a molecular diagnostic assay that uses a direct nucleic acid probe to detect Human Herpesvirus 6 (HHV-6). This test supports clinical diagnosis of HHV-6–related illness, including roseola in children and more severe presentations in immunocompromised adults. Molecular detection of HHV-6 has national clinical relevance for timely diagnosis and infection management pathways in both inpatient and outpatient settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for HHV-6 testing, the typical service setting, and the elements that influence billing and coverage decisions for molecular infectious disease assays. The publication summarizes common modifiers associated with laboratory services and notes where input data are not available.

This document is intended to inform billing staff, laboratory managers, and policy analysts about the code’s clinical meaning, expected service environment, and the scope of payer coverage discussion. It highlights what readers can expect: benchmarks and coverage themes, relevant policy considerations for laboratory molecular testing, and the clinical scenarios that commonly prompt ordering of CPT code 87531.